RxDoctor Payments Data

Erin Amato, MD

Psychiatry · Billings, MTNPI 1447425178

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $77,420 of the $87,925 with a category attached, or 88.1%. Johnson & Johnson accounts for 99.8% of it on its own, with 7 other manufacturers making up the rest. Among psychiatry clinicians in MT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$87,925in general payments, 2019–2025

Across 124 payments — averaging $709.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$88K
  • AbbVie$59
  • Novo Nordisk$32
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$32
  • Alkermes, Inc.$23
  • Supernus Pharmaceuticals, Inc.$21
  • plus $34 from 2 others

What the payments were for

  • Speaking & faculty fees$77,42088%
  • Travel & lodging$7,8529%
  • Food & beverage$2,6533%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$87,925 in reported general payments places this provider in the 95th percentile of 82 psychiatry providers in Montana.

See all psychiatry providers in Montana

Medicare billing

Part B allowed, 2024
$66,150
Medicare patients
43
Services billed
655

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Bupropion XlBupropion Hcl84$1,775
Desvenlafaxine Succinate ErDesvenlafaxine Succinate21$1,072
Vilazodone Hcl22$831
Olanzapine18$621
Prazosin Hcl13$435
Lurasidone Hcl16$396
Duloxetine Hcl12$377
Quetiapine Fumarate20$342
Gabapentin13$295
Trazodone Hcl41$280
Mirtazapine17$200
Sertraline Hcl12$183
Lorazepam15$54
Clonazepam14$39

Paid to pharmacies, not to this prescriber.

Other psychiatry in Billings

See the full list for Montana

Where these figures come from

Is this you, or does something look wrong? →